GANC — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1469250	1.00	2/20
SCHEMBL1479404	1.00	2/20
SCHEMBL1879685	1.00	2/20
SCHEMBL2265529	1.00	2/20
SCHEMBL2265531	1.00	2/20
SCHEMBL7811568	1.00	2/20
SCHEMBL7824407	1.00	2/20
SCHEMBL9379987	1.00	2/20
SCHEMBL13298780	1.00	2/20
SCHEMBL13298798	1.00	2/20
SCHEMBL14654237	1.00	2/20
SCHEMBL18271004	1.00	2/20
SCHEMBL20466285	1.00	2/20
Hydrochloric Acid (SCHEMBL3378151)	0.94	2/20
Hydrochloric Acid (SCHEMBL9379547)	0.94	2/20
SCHEMBL466573	0.93	2/20
SCHEMBL466574	0.93	2/20
SCHEMBL2434435	0.93	2/20
SCHEMBL2435520	0.93	2/20
SCHEMBL4319863	0.93	2/20

Clinical trials — most relevant to GANC by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment	PHASE4	COMPLETED
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes	PHASE4	RECRUITING
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients	PHASE3	COMPLETED
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)	PHASE3	COMPLETED
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3	PHASE3	COMPLETED
A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease	PHASE3	COMPLETED
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase	PHASE2/PHASE3	COMPLETED
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension	PHASE2	ACTIVE_NOT_RECRUITING
Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)	PHASE1/PHASE2	COMPLETED
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease	PHASE2	COMPLETED
Ambroxol as a Treatment for Parkinson's Disease Dementia	PHASE2	UNKNOWN
Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease	PHASE1/PHASE2	UNKNOWN
Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease	PHASE2	COMPLETED
A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine	PHASE1	COMPLETED
Extra Virgin Olive Oil on Glycemic Control ,Insulin Resistance and Insulin Secretion	nan	UNKNOWN
Effect of an Polyphenolic Beverage in Healthy Volunteers	nan	ACTIVE_NOT_RECRUITING
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease	nan	COMPLETED
Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study)	nan	COMPLETED
A Long Term Follow up Study in Late-onset Pompe Disease	nan	UNKNOWN
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
Biomarker for Glycogen Storage Diseases (BioGlycogen)	nan	WITHDRAWN
Effect of Migalastat on Cardiac Involvement in Fabry Disease	nan	COMPLETED
Pregnancy and Birth Outcome in Women With Pompe Disease	nan	COMPLETED
Newborn Screening Assay of Pompe's Disease	nan	COMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Combination of Bitter Melon Extract and Snakehead Fish Powder to Reduce Glycaemia in Type 2 Diabetes Mellitus	nan	COMPLETED
A Prospective, Observational Study in Patients With Late-Onset Pompe Disease	nan	COMPLETED
Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia	nan	UNKNOWN
Biomarker for Pompe Disease (BioPompe)	nan	WITHDRAWN
Study to Determine Mutations in the Gaucher Gene in Patients With Idiopathic Parkinson's Disease for Phenotype-genotype Correlation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GANC binder may also engage these)

Protein	Name	Similarity
Q9BE70	—	0.999	Q9BE70 →
Q94502	—	0.992	Q94502 →
Q8BVW0	—	0.992	Q8BVW0 →
Q9US55	—	0.989	Q9US55 →
P70699	—	0.989	P70699 →
D4B0X3	—	0.988	D4B0X3 →
MGAM	Maltase-glucoamylase	0.988	landscape →
Q9FN05	—	0.987	Q9FN05 →
F4J6T7	—	0.987	F4J6T7 →
Q9S7Y7	—	0.986	Q9S7Y7 →
P38138	—	0.986	P38138 →
Q9VTJ4	—	0.985	Q9VTJ4 →
Q92442	—	0.985	Q92442 →
MGAM2	Probable maltase-glucoamylase 2 (Maltase-gluc	0.984	landscape →
Q6P7A9	—	0.984	Q6P7A9 →
P79403	—	0.983	P79403 →
Q8BHN3	—	0.983	Q8BHN3 →
GANAB	Neutral alpha-glucosidase AB	0.983	landscape →
O04931	—	0.982	O04931 →
P17164	—	0.982	P17164 →
Q99LJ1	—	0.982	Q99LJ1 →
O62653	—	0.982	O62653 →
A1CNK4	—	0.981	A1CNK4 →
Q9QWR8	—	0.981	Q9QWR8 →
Q619W7	—	0.981	Q619W7 →
SI	Sucrase-isomaltase, intestinal	0.981	landscape →
P07191	—	0.981	P07191 →
O04893	—	0.981	O04893 →
B0XAA1	—	0.981	B0XAA1 →
GAA	Lysosomal alpha-glucosidase	0.981	landscape →